Get the Stockscreener App
121.00
13.47%
14.36
After Hours:
122.00
1.00
+0.83%
Glaukos Corporation stock is traded at $121.00, with a volume of 1.79M.
It is up +13.47% in the last 24 hours and up +0.63% over the past month.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
See More
Previous Close:
$106.64
Open:
$103.55
24h Volume:
1.79M
Relative Volume:
2.11
Market Cap:
$6.95B
Revenue:
$360.35M
Net Income/Loss:
$-149.57M
P/E Ratio:
-40.88
EPS:
-2.96
Net Cash Flow:
$-81.27M
1W Performance:
+10.98%
1M Performance:
+0.63%
6M Performance:
+35.17%
1Y Performance:
-20.89%
1-Day Range:
$103.55
$121.69
1-Week Range:
$103.55
$121.69
52-Week Range:
$73.16
$161.78
Glaukos Corporation Stock (GKOS) Company Profile
Name
Glaukos Corporation
Sector
Industry
Phone
949-367-9600
Address
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
121.00 | 6.12B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
113.29 | 195.21B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
377.32 | 141.28B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
98.49 | 123.60B | 35.48B | 4.64B | 5.41B | 3.5856 |
|
BSX
Boston Scientific Corp
|
76.28 | 113.14B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
78.98 | 45.52B | 6.07B | 1.06B | 799.60M | 1.8527 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-01-25 | Initiated | Goldman | Buy |
| May-01-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-19-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-06-24 | Initiated | UBS | Buy |
| Dec-02-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-10-24 | Downgrade | Citigroup | Buy → Neutral |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-21-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-28-23 | Initiated | Truist | Buy |
| Nov-08-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-07-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-19-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-04-22 | Initiated | Needham | Buy |
| Jul-12-22 | Upgrade | Stifel | Hold → Buy |
| Feb-03-22 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-19-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jan-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Jul-26-21 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jul-20-21 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jul-14-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-08-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Upgrade | Citigroup | Sell → Neutral |
| Dec-09-20 | Initiated | Oppenheimer | Perform |
| Nov-17-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-15-20 | Initiated | Jefferies | Hold |
| Mar-05-20 | Initiated | Citigroup | Sell |
| Feb-28-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-20 | Upgrade | Berenberg | Hold → Buy |
| Dec-12-19 | Downgrade | Wells Fargo | Outperform → Underperform |
| Sep-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Mar-08-19 | Initiated | BTIG Research | Neutral |
| Aug-30-18 | Initiated | Berenberg | Hold |
| Aug-29-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-03-18 | Reiterated | Stifel | Hold |
| Jun-21-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-13-18 | Downgrade | Stifel | Buy → Hold |
| Mar-01-18 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-02-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-06-17 | Upgrade | Stifel | Hold → Buy |
| Oct-27-16 | Initiated | Wells Fargo | Outperform |
View All
Glaukos Corporation Stock (GKOS) Latest News
Glaukos Corp. Earnings Call Signals High-Growth Phase - TipRanks
Glaukos (NYSE:GKOS) Jumps After Qtrly Revenue Beat - Kalkine Media
Glaukos (NYSE:GKOS) Trading 8.4% HigherWhat's Next? - MarketBeat
Glaukos Stock Shoots Up After iDose TR Re-administration Approval - StocksToTrade
Stifel reiterates Glaukos stock rating on product momentum - Investing.com
Glaukos (GKOS): Wells Fargo Raises Price Target to $135 | GKOS S - GuruFocus
Needham raises Glaukos stock price target on iDose, Epioxa growth - Investing.com
BTIG Research Reaffirms Buy Rating for Glaukos (NYSE:GKOS) - MarketBeat
Glaukos Corporation (NYSE:GKOS) Q4 2025 Earnings Call Transcript - Insider Monkey
BTIG Reiterates Buy Rating for Glaukos (GKOS) with Unchanged Pri - GuruFocus
Glaukos (GKOS) Surpasses Revenue Expectations with Strong Q4 Per - GuruFocus
Glaukos Reports Fourth Quarter and Full Year 2025 Financial Results - VisionMonday.com
Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results - BioSpace
Glaukos Corp (GKOS) Q4 2025 Earnings Call Highlights: Record Sal - GuruFocus
Glaukos Q4 Earnings Call Highlights - MarketBeat
Glaukos (GKOS) Q4 2025 Earnings Call Transcript - The Globe and Mail
Glaukos (GKOS) Anticipates $600M-$620M Revenue for FY26 - GuruFocus
Glaukos (GKOS) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance UK
Glaukos (GKOS) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Glaukos: Q4 Earnings Snapshot - kens5.com
Glaukos Reports Record Q4 Sales, Reaffirms 2026 Outlook - TipRanks
Glaukos (NYSE:GKOS) Issues Earnings Results - MarketBeat
Glaukos Q4 Non-GAAP Loss Narrows, Sales Rise - marketscreener.com
Glaukos Q4 Earnings Summary & Key Takeaways - Benzinga
Earnings Flash (GKOS) Glaukos Corporation Reports Q4 Revenue $143.1M, vs. FactSet Est of $136.4M - marketscreener.com
Insider Buy: Why is Glaukos Corporation stock going up2025 Analyst Calls & Community Consensus Trade Alerts - baoquankhu1.vn
Glaukos earnings on deck as iDose, Epioxa launches converge - Investing.com UK
Glaukos earnings on deck as iDose, Epioxa launches converge By Investing.com - Investing.com India
Glaukos: Fourth Quarter Financial Highlights - Bitget
Wellington Management Group LLP Significantly Reduces Stake in G - GuruFocus
Glaukos Corporation (GKOS) Investor Outlook: Analyzing the 21% Potential Upside Amid Robust Revenue Growth - DirectorsTalk Interviews
Can Glaukos Corporation stock hit record highs againJuly 2025 Opening Moves & Safe Entry Momentum Tips - mfd.ru
Aug Movers: Is Glaukos Corporation a defensive stock2025 Retail Activity & Safe Entry Momentum Tips - baoquankhu1.vn
Glaukos (GKOS) Q4 Earnings Preview: Revenue Growth Expected - GuruFocus
Public Sector Pension Investment Board Purchases 28,866 Shares of Glaukos Corporation $GKOS - MarketBeat
Should I buy Glaukos Corporation (6GJ) stock before earnings seasonJuly 2025 Trends & Technical Pattern Based Signals - mfd.ru
Is Glaukos Corporation stock positioned for long term growthJuly 2025 Drop Watch & Technical Entry and Exit Alerts - mfd.ru
(GKOS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Does Glaukos Corporation meet Warren Buffett’s criteriaWeekly Trend Recap & Capital Efficient Trading Techniques - mfd.ru
Why Glaukos Corporation stock remains undervaluedQuarterly Profit Review & Verified Chart Pattern Signals - mfd.ru
Globus Medical (GMED) to Report Q4 Results: Wall Street Expects Earnings Growth - Finviz
Stifel reiterates Buy rating on Glaukos stock with $160 price target By Investing.com - Investing.com Nigeria
Stifel reiterates Buy rating on Glaukos stock with $160 price target - Investing.com Australia
Glaukos (GKOS) Expected to Beat Earnings Estimates: Should You Buy? - Finviz
What is Glaukos Corporation’s market position2025 Major Catalysts & Weekly Momentum Picks - mfd.ru
Glaukos (GKOS) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Glaukos Corporation $GKOS Shares Sold by New York State Common Retirement Fund - MarketBeat
Glaukos (NYSE:GKOS) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat
C WorldWide Group Holding A S Acquires 45,000 Shares of Glaukos Corporation $GKOS - MarketBeat
How FDA Approval of Repeat iDose TR Use Will Impact Glaukos (GKOS) Investors - simplywall.st
Glaukos Corporation $GKOS Shares Sold by Brown Capital Management LLC - MarketBeat
Glaukos Corporation Stock (GKOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):